Ascentage reports Phase I data for APG-1252 in solid tumors
Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) reported interim data from 13 evaluable patients with solid tumors, including six with small cell lung cancer (SCLC), in a Phase I trial showing that APG-1252 led to one confirmed partial response in a patient with metastatic NSCLC. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Patients in the open-label, U.S. trial received twice-weekly 10-400 mg doses of IV APG-1252. APG-1252 was well tolerated with no adverse events leading to treatment discontinuation or hematological toxicity reported. The maximum tolerated dose (MTD) has not yet been reached...